Number of SEER-MHOS Respondents (Age 65+) by Selected First Cancer Site, 1998-2013

First Cancer Total Number of linked Patients Baseline Survey
(Group A)
Baseline and Follow-up Surveys
(Subset of Group A)
Baseline Survey before Cancer Diagnosis
(Group B)
Survey before and
after Cancer
Diagnosis*
(Subset of Group B)
Baseline Survey after Cancer Diagnosis
(Group C)
N % N % N % N % N %
Prostate (28010)  25,424 25,253 (99.33) 11,192 (44.02) 7,344 (28.89) 1,732 (6.81) 19,638 (77.24)
Breast (26000) 21,470 21,299 (99.20) 10,040 (46.76) 5,771 (26.88) 1,331 (6.20) 16,856 (78.51)
Colorectal (21041-21052) 13,989 13,904 (99.39) 6,052 (43.26) 5,265 (37.64) 899 (6.43) 9,537 (68.17)
Lung and bronchus (22030) 10,060 9,973 (99.14) 3,588 (35.67) 7,377 (73.33) 588 (5.84) 3,181 (31.62)
Ovary(27040) 1,294 1,286 (99.38) 547 (42.27) 620 (47.91) 64 (4.95) 730 (56.41)
Uterus(27020, 27030) 3,993 3,961 (99.20) 1,877 (47.01) 898 (22.49) 184 (4.61) 3,247 (81.32)
Cervix (27010) 1,553 1,533 (98.71) 671 (43.21) 120 (7.73) 14 (0.90) 1,427 (91.89)
Bladder (29010) 6,148 6,102 (99.25) 2,637 (42.89) 2,460 (40.01) 434 (7.06) 4,076 (66.30)
Melanomas -- skin (25010) 5,983 5,934 (99.18) 2,816 (47.07) 2,149 (35.92) 415 (6.94) 4,188 (70.00)
Head and Neck (20010-20100,22010,22020) 3,010 2,986 (99.20) 1,278 (42.46) 1,076 (35.75) 180 (5.98) 2,090 (69.44)
Kidney and Renal pelvis (29020) 2,524 2,508 (99.37) 1,077 (42.67) 1,163 (46.08) 203 (8.04) 1,548 (61.33)
Non-Hodgkin's lymphomas -- nodal and extranodal (33041,33042) 3,702 3,670 (99.14) 1,608 (43.44) 1,867 (50.43) 261 (7.05) 2,063 (55.73)
Stomach (21020) 1,365 1,357 (99.41) 501 (36.70) 894 (65.49) 71 (5.20) 534 (39.12)
Pancreas (21100) 1,691 1,680 (99.35) 567 (33.53) 1,505 (89.00) 67 (3.96) 242 (14.31)

* Number of individuals with a baseline survey before their first cancer diagnosis and also a baseline or follow-up survey after their first cancer diagnosis.

Note:

  1. The denominator for the percentages that appear in columns 3 through 7 is the Total Number of Linked Patients with completed or partially completed surveys by cancer site (column 2). The groups in columns 3 through 7 are not mutually exclusive, therefore, the percentages do not sum to 100.
  2. (Group B + Group C) > Group A because some patients participated in more than one MHOS cohort and completed at least one baseline survey before cancer diagnosis and at least one baseline survey after first cancer diagnosis.